Prognostic significance of endothelial Per-Arnt-Sim domain protein 1/hypoxia-inducible factor-2α expression in a subset of tumor associated macrophages in invasive bladder cancer

Journal of Urology

Volumn 171, Issue 3, 2004, Pages 1080-1084

  Koga, Fumitaka ^a   Kageyama, Yukio ^a   Kawakami, Satoru ^a   Fujii, Yasuhisa ^a   Hyochi, Nobuhiko ^a   Ando, Noboru ^a   Takizawa, Touichiro ^a   Saito, Kazutaka ^a   Iwai, Aki ^a   Masuda, Hitoshi ^a   Kihara, Kazunori ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

bHLH PAS factor HLF; Bladder; Carcinoma, transitional cell; Macrophages

Indexed keywords

CELL PROTEIN; ENDOTHELIAL PER ARNT SIM DOMAIN PROTEIN 1; HYPOXIA INDUCIBLE FACTOR 2ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; BLADDER CANCER; CANCER GRADING; CANCER INVASION; CANCER SURVIVAL; CELL COUNT; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TUMOR ASSOCIATED LEUKOCYTE;

EID: 12144287073     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000110541.62972.08     Document Type: Article

References (21)

1. Lewis, J. S., Lee, J. A., Underwood, J. C., Harris, A. L. and Lewis, C. E.: Macrophage responses to hypoxia: relevance to disease mechanisms. J Leukoc Biol, 66: 889, 1999
2. Bingle, L., Brown, N. J. and Lewis, C. E.: The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol, 196: 254, 2002
3. Bunn, H. F. and Poyton, R. O.: Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev, 76: 839, 1996
4. Brizel, D. M., Scully, S. P., Harrelson, J. M., Layfield, L. J., Bean, J. M., Prosnitz, L. R. et al: Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res, 56: 941, 1996
5. Wang, G. L. and Semenza, G. L.: Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem, 268: 21513, 1993
6. Tian, H., McKnight, S. L. and Russell, D. W.: Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev, 11: 72, 1997
7. Blancher, C. and Harris, A. L.: The molecular basis of the hypoxia response pathway: tumour hypoxia as a therapy target. Cancer Metastasis Rev, 17: 187, 1998
8. Dachs, G. U., Patterson, A. V., Firth, J. D., Ratcliffe, P. J., Townsend, K. M., Stratford, I. J. et al: Targeting gene expression to hypoxic tumor cells. Nat Med, 3: 515, 1997
9. Talks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J. et al: The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol, 157: 411, 2000
10. Onita, T., Ji, P. G., Xuan, J. W., Sakai, H., Kanetake, H., Maxwell, P. H. et al: Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer. Clin Cancer Res, 8: 471, 2002
11. Leek, R. D., Talks, K. L., Pezzella, F., Turley, H., Campo, L., Brown, N. S. et al: Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in human breast cancer. Cancer Res, 62: 1326, 2002
12. Mostofi, F. K.: Histological Typing of Urinary Bladder Tumours. Geneva: World Health Organization, 1973
13. Sobin, L. H. and Wittekind, C. H.: UICC-TNM Classification of Malignant Tumours. New York: Wiley-Liss, 1997
14. Xia, G., Kageyama, Y., Hayashi, T., Kawakami, S., Yoshida, M. and Kihara, K.: Regulation of vascular endothelial growth factor transcription by endothelial PAS domain protein 1 (EPAS1) and possible involvement of EPAS1 in the angiogenesis of renal cell carcinoma. Cancer, 91: 1429, 2001
15. Koga, F., Kawakami, S., Kumagai, J., Takizawa, T., Ando, N., Arai, G. et al: Impaired delta Np63 expression associates with reduced beta-catenin and aggressive phenotypes of urothelial neoplasms. Br J Cancer, 88: 740, 2003
16. Grossman, H. B.: Superficial bladder cancer: decreasing the risk of recurrence. Oncology, 10: 1617, 1996
17. Lee, R. and Droller, M. J.: The natural history of bladder cancer. Implications for therapy. Urol Clin North Am, 27: 1, 2000
18. Steinberg, G. D., Trump, D. L. and Cummings, K. B.: Metastatic bladder cancer. Natural history, clinical course, and consideration for treatment. Urol Clin North Am, 19: 735, 1992
19. Hanada, T., Nakagawa, M., Emoto, A., Nomura, T., Nasu, N. and Nomura, Y.: Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol, 7: 263, 2000
20. Bryne, M., Boysen, M., Alfsen, C. G., Abeler, V. M., Sudbo, J., Nesland, J. M. et al: The invasive front of carcinomas. The most important area for tumour prognosis? Anticancer Res, 18: 4757, 1998
21. Kung, A. L., Wang, S., Klco, J. M., Kaelin, W. G. and Livingston, D. M.: Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med, 6: 1335, 2000